Showing 1821-1830 of 3223 results for "".
- Shamir Launches Spark 4W Digital Electro-Optic Measurement Systemhttps://modernod.com/news/shamir-launches-spark-4w-digital-electro-optic-measurement-system/2482101/Shamir announced the launch of the Spark 4W, a digital electro-optic measurement system based on 3D stereo vision technology and artificial intelligence (AI) elements. Shamir Spark 4W is designed to enable eye care professionals (ECPs) to obtain precise and automatic meas
- Alcon Canada Launches TOTAL30 Multifocal Contact Lenses for Reusable Lens Patients with Presbyopiahttps://modernod.com/news/alcon-canada-launches-total30-multifocal-contact-lenses-for-reusable-lens-patients-with-presbyopia/2482093/Alcon announced the launch of TOTAL30 Multifocal in Canada, the first and only monthly water gradient multifocal contact lens. The new TOTAL30 Multifocal lens is designed to help digital device dryness by utilizing a proprietary water gradient technology to deliver nearly
- Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512 for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-positive-topline-results-from-phase-3-comet-trials-of-ar-15512-a-novel-topical-drug-candidate-for-dry-eye/2482063/Alcon announced positive topline results from the two pivotal phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of dry eye disease (DED). In both COMET-2 and COMET-3, which enrolled more than 93
- Alkeus’ Gildeuretinol Studied to Halt Progression of Early-Stage Stargardt Diseasehttps://modernod.com/news/alkeus-gildeuretinol-studied-to-halt-progression-of-early-stage-stargardt-disease/2482055/Alkeus Pharmaceuticals announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to 6 years in the ongoing TEASE-3 clinical trial. The first three teenage patients with early-stage Stargardt disease enrolled in the trial and treated with oral gild
- Alimera Completes Recruitment for the Synchronicity Study Evaluating Yutiqhttps://modernod.com/news/alimera-completes-recruitment-for-the-synchronicity-study-evaluating-yutiq/2482044/Alimera Sciences announced that it has completed enrollment for the company’s Synchronicity study, a prospective, open-label clinical study evaluating the safety and efficacy of Yutiq (fluocinolone acetonide intravitreal implant 0.18mg) in the treatment of chronic noninfectious uveitis
- Annexon Outlines Registrational Program For ANX007 in GA with FDA Alignment On Vision Preservation As Primary Endpointhttps://modernod.com/news/annexon-outlines-registrational-program-for-anx007-in-ga-with-fda-alignment-on-vision-preservation-as-primary-endpoint/2482025/Annexon outlined its global registrational program for ANX007, a first-in-class C1q and classical complement inhibitor, for the treatment of patients with geographic atrophy (GA). Annexon has gained alignment with the FDA on a phase 3 registration program that includes using,
- Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLshttps://modernod.com/news/alcon-canada-launches-clareon-vivity-its-latest-advancement-in-presbyopia-correcting-iols/2481956/Alcon announced that Clareon Vivity, the first and only non-diffractive extended depth of focus (EDOF) IOL on Alcon’s lens platform, is now available in Canada. [1-6] Clareon Vivity is designed to provide high-quality vision from distance to functional near with a visual dist
- Alcon Showcases Cloud-Based Planning and Digital Technologies During AAO 2023https://modernod.com/news/alcon-showcases-cloud-based-planning-and-digital-technologies-during-aao-2023/2481930/At the upcoming American Academy of Ophthalmology (AAO) 2023 annual meeting in San Francisco, Alcon will provide connected equipment ecosystems via its digital innovation technology. Ophthalmologists, surgical staff, researchers, and industry leaders will have the opportunity to ex
- AbbVie Enters into Option Agreement with Aldeyra Therapeutics for License to Develop and Commercialize Reproxalaphttps://modernod.com/news/abbvie-enters-into-option-agreement-with-aldeyra-therapeutics-for-license-to-develop-and-commercialize-reproxalap/2481929/Aldeyra Therapeutics announced that it has entered into an exclusive option agreement with AbbVie in which AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in the US, and an exclusive license to develop, manufacture, and comme
- Lensar and Oertli Provide Update on Plans to Integrate Phaco Technology into the ALLY Adaptive Cataract Treatment Systemhttps://modernod.com/news/lensar-and-oertli-provide-update-on-plans-to-integrate-phaco-technology-into-the-ally-adaptive-cataract-treatment-system/2481923/Lensar said it is closer to its plans to integrate phacoemulsification technology from Oertli Instrumente into the ALLY Adaptive Cataract Treatment System. Oertli filed with the FDA a 510(k) for their Faros device, which if cleared, will bring Lensar a step closer to deliver comb